Envista (NYSE:NVST) Earns "Hold" Rating from Needham & Company LLC

Needham & Company LLC reiterated their hold rating on shares of Envista (NYSE:NVST - Free Report) in a report released on Thursday,Benzinga reports.

Several other research firms have also recently commented on NVST. Robert W. Baird boosted their price objective on shares of Envista from $17.00 to $22.00 and gave the company a "neutral" rating in a research report on Thursday, October 31st. Mizuho began coverage on Envista in a report on Wednesday, December 4th. They issued an "underperform" rating and a $20.00 price target on the stock. Piper Sandler increased their price objective on Envista from $17.00 to $18.00 and gave the stock a "neutral" rating in a report on Monday, February 3rd. Leerink Partners upgraded Envista from an "underperform" rating to a "market perform" rating and boosted their target price for the company from $16.00 to $23.00 in a research note on Thursday, October 31st. Finally, Stifel Nicolaus raised their price target on shares of Envista from $18.00 to $21.00 and gave the stock a "buy" rating in a research note on Wednesday, October 23rd. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $20.21.

Envista Trading Down 0.0 %

NYSE:NVST traded down $0.01 on Thursday, reaching $21.24. The company's stock had a trading volume of 1,649,792 shares, compared to its average volume of 2,248,701. Envista has a 1-year low of $15.15 and a 1-year high of $23.06. The business's 50-day moving average price is $19.94 and its two-hundred day moving average price is $19.20. The firm has a market cap of $3.66 billion, a PE ratio of -3.27, a PEG ratio of 2.06 and a beta of 1.34. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.77 and a current ratio of 2.04.

Envista (NYSE:NVST - Get Free Report) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.23 by $0.01. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%. Equities research analysts anticipate that Envista will post 1.06 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Envista

Hedge funds have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Envista in the third quarter valued at approximately $31,000. GAMMA Investing LLC grew its holdings in Envista by 69.8% in the 3rd quarter. GAMMA Investing LLC now owns 1,766 shares of the company's stock valued at $35,000 after buying an additional 726 shares in the last quarter. Huntington National Bank increased its position in Envista by 97.8% during the 3rd quarter. Huntington National Bank now owns 1,919 shares of the company's stock worth $38,000 after buying an additional 949 shares during the period. Venturi Wealth Management LLC lifted its holdings in shares of Envista by 528.4% during the fourth quarter. Venturi Wealth Management LLC now owns 1,948 shares of the company's stock worth $38,000 after buying an additional 1,638 shares in the last quarter. Finally, Blue Trust Inc. boosted its position in shares of Envista by 69.7% in the third quarter. Blue Trust Inc. now owns 1,957 shares of the company's stock valued at $39,000 after acquiring an additional 804 shares during the period.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.